

Bone Therapeutics announces its financial calendar for 2017

Gosselies, Belgium, 21 December 2016 - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases, today announces its financial calendar for 2017.

Bone Therapeutics – Financial Calendar 2017:

- 17 January 2017 – Q4 2016 Business Highlights and Cash Position Update
- 16 March 2017 – Full Year Results 2016
- 19 April 2017 – Annual Report 2016
- 11 May 2017 – Q1 2017 Business and Financial Highlights
- 26 May 2017 – Annual General Meeting 2017
- 31 August 2017 – Half Year Results 2017
- 9 November 2017 – Q3 2017 Business and Financial Highlights

This schedule is indicative and subject to change. The calendar is also available on the Bone Therapeutics website under the heading [Investors](#).

In addition, Bone Therapeutics announces that it will participate in the following investor conferences in January 2017:

- 6 January 2017 – Oddo Midcap Forum, Lyon (France)
- 26 January 2017 – Invest Securities BioMed Event, Paris (France)

-Ends-

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for orthopaedics and bone diseases. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB[®], Bone Therapeutics' autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase IIA for severe osteoporosis. ALLOB[®], its allogeneic "off-the-shelf" bone cell product, is in Phase I/IIA for the treatment of delayed-union fractures, lumbar fusion for degenerative disease of the spine and revision spinal fusion. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 10 patent families. Further information is available at www.bonetherapeutics.com.

For more information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Thomas Lienard, Chief Executive Officer
Wim Goemaere, Chief Financial Officer

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5701

Jonathan Birt, Jessica Hodgson, Lindsey Neville
and Hendrik Thys

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries

NewCap Investor Relations & Financial Communications

Tel: + 33 (0)2 44 71 94 94

Pierre Laurent, Louis-Victor Delouvrier and
Nicolas Merigeau

bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.